Université Henri Poincaré, Nancy Université, Nancy, France.
Pflugers Arch. 2011 Mar;461(3):317-24. doi: 10.1007/s00424-010-0911-4. Epub 2010 Dec 17.
With the advancement of medical and investigative science, it is somewhat surprising that although it is possible to stabilise medical patients with hypertension and the associated kidney dysfunction, obesity, diabetes and even cancer, there is still no clear method of significantly reducing these chronic disease pathologies, and thus, extending life expectancy. There is one hormone common to these pathologies, the antagonism of which goes some way to clinical improvements, and this is angiotensin, which is released during hypovolaemia. Angiotensin antagonists are used to treat many of these pathologies, and it has been shown in the obesity literature that angiotensin antagonists decrease weight, but also increase the drinking of water. Increased cellular hydration, and hence, improved mitochondrial metabolism could be one of the mechanisms for the reduction in weight seen in these studies, as well as for reducing the other pathologies, all showing metabolic dysfunction. It appears that the application of straightforward physiological regulation might be an appropriate medical approach to the prevention of hypertension, kidney disease, obesity, diabetes and cancer, and thus, to an increased life expectancy.
随着医学和研究科学的进步，令人有些惊讶的是，尽管有可能稳定患有高血压和相关肾功能障碍、肥胖症、糖尿病甚至癌症的医疗患者，但仍然没有明确的方法可以显著减少这些慢性疾病病理，从而延长预期寿命。这些病理有一种共同的激素，即血管紧张素，其拮抗作用在一定程度上改善了临床状况，血管紧张素在低血容量时释放。血管紧张素拮抗剂被用于治疗许多这些病理，肥胖症文献表明血管紧张素拮抗剂可以减轻体重，同时也增加水的摄入。细胞水合作用增加，从而线粒体代谢改善，可能是这些研究中体重减轻的机制之一，也可能是减轻其他病理的机制之一，所有这些病理都显示出代谢功能障碍。似乎应用简单的生理调节可能是预防高血压、肾脏疾病、肥胖症、糖尿病和癌症以及提高预期寿命的一种适当的医疗方法。
